- Home
- CITEU vs IMNM Comparison
CITEU vs IMNM Comparison
Compare CITEU & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CITEU
- IMNM
- Stock Information
- Founded
- CITEU N/A
- IMNM 2006
- Country
- CITEU
- IMNM United States
- Employees
- CITEU 2
- IMNM N/A
- Industry
- CITEU
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CITEU
- IMNM Health Care
- Exchange
- CITEU NYSE
- IMNM Nasdaq
- Market Cap
- CITEU N/A
- IMNM 747.7M
- IPO Year
- CITEU N/A
- IMNM 2020
- Fundamental
- Price
- CITEU $11.70
- IMNM $10.97
- Analyst Decision
- CITEU
- IMNM Strong Buy
- Analyst Count
- CITEU 0
- IMNM 5
- Target Price
- CITEU N/A
- IMNM $28.60
- AVG Volume (30 Days)
- CITEU N/A
- IMNM 911.8K
- Earning Date
- CITEU N/A
- IMNM 11-13-2024
- Dividend Yield
- CITEU N/A
- IMNM N/A
- EPS Growth
- CITEU N/A
- IMNM N/A
- EPS
- CITEU N/A
- IMNM N/A
- Revenue
- CITEU N/A
- IMNM $10,129,000.00
- Revenue This Year
- CITEU N/A
- IMNM N/A
- Revenue Next Year
- CITEU N/A
- IMNM N/A
- P/E Ratio
- CITEU N/A
- IMNM N/A
- Revenue Growth
- CITEU N/A
- IMNM N/A
- 52 Week Low
- CITEU N/A
- IMNM $8.33
- 52 Week High
- CITEU N/A
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- CITEU 98.52
- IMNM 39.61
- Support Level
- CITEU $11.31
- IMNM $10.76
- Resistance Level
- CITEU $13.28
- IMNM $15.13
- Average True Range (ATR)
- CITEU 0.00
- IMNM 0.98
- MACD
- CITEU 0.02
- IMNM -0.29
- Stochastic Oscillator
- CITEU 100.00
- IMNM 4.81
About CITEU CARTICA ACQUISITION CORP UNIT 1 CL A SHS & 1/2 RED WT EXP30/04/28
Cartica Acquisition Corp is a blank check company.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.